FDA inspection practices are evolving in 2026, making inspection readiness an increasingly important priority for pharmaceutical, biologics, medical device, and other regulated organizations. The U.S. Food and Drug Administration is adopting more targeted, risk-based approaches to oversight while continuing to evaluate whether manufacturers maintain effective quality systems and comply with applicable regulatory requirements. Organizations should therefore view FDA GMP Inspections not simply as periodic regulatory events, but as an ongoing test of the effectiveness and maturity of their quality systems.

One significant development in 2026 is FDA’s pilot of one-day inspectional assessments. Launched in April 2026, these shorter assessments are designed to complement traditional FDA inspections by providing targeted screening of facilities and expanding the Agency’s oversight coverage. FDA states that facilities are selected using risk-based criteria, including product type, previous inspection outcomes, and operational characteristics. Although these assessments are not intended to replace standard inspections, FDA investigators may expand the assessment when significant observations are identified.

This development reinforces the importance of FDA Inspection Readiness. Companies should not assume that a shorter inspection means a lower level of regulatory scrutiny. A focused assessment may require rapid access to critical quality records, knowledgeable subject-matter experts, accurate responses, and evidence that the organization’s quality system is functioning effectively. Inspection readiness therefore needs to be maintained continuously rather than developed only after receiving an inspection notice.

For medical device manufacturers, the regulatory environment has changed significantly. On February 2, 2026, FDA’s Quality Management System Regulation (QMSR) became effective, incorporating ISO 13485:2016 by reference into the device CGMP framework. At the same time, FDA discontinued the previous Quality System Inspection Technique (QSIT) and began using the inspection process described in the updated Medical Device Manufacturers Compliance Program 7382.850.

The new QMSR inspection approach places additional importance on understanding how the organization’s quality management system operates as a whole. FDA investigators may review records associated with quality audits, management review, and supplier audits that were previously subject to specific inspection limitations under the former QS regulation. Manufacturers should therefore ensure that these records are complete, accurate, controlled, and readily retrievable.

For pharmaceutical and biologics manufacturers, strong GMP Compliance remains the foundation of inspection preparedness. Quality systems should demonstrate effective control of manufacturing processes, facilities, equipment, materials, laboratory operations, documentation, deviations, investigations, CAPA, change control, training, and supplier oversight. FDA’s current inspection strategy also increasingly incorporates risk-based tools and alternative assessment approaches, including Remote Regulatory Assessments and remote interactive evaluations where appropriate.

Data integrity should remain a central inspection-readiness priority. Investigators may evaluate whether records are complete, accurate, attributable, contemporaneous, original or true copies, and readily available for review. Companies should verify that electronic systems have appropriate controls, audit trails are reviewed where required, and personnel understand their responsibilities for maintaining reliable records.

A strong inspection-readiness program should also focus on the effectiveness of the quality system rather than simply preparing documents for an investigator. Internal audits, management reviews, quality metrics, deviation trends, CAPA effectiveness, supplier performance, and recurring compliance issues can reveal weaknesses before they become FDA observations. Organizations should use these quality signals to identify systemic problems and implement sustainable corrective and preventive actions.

Employee preparedness is equally important. Personnel who interact with FDA investigators should understand their roles, know how to retrieve controlled records, communicate accurately, and avoid speculation when responding to regulatory questions. Subject-matter experts should be available to explain critical processes and quality decisions using objective evidence. Inspection training should focus on appropriate communication and regulatory expectations rather than rehearsed responses.

Companies should also evaluate whether their written procedures accurately reflect actual operations. A gap between approved SOPs and observed practices can create significant compliance risk. Periodic internal assessments should compare procedures with actual workflows and determine whether changes are needed to documentation, training, systems, or controls.

The shift toward more targeted and risk-based oversight means that organizations need greater visibility into their own compliance risks. FDA’s 2026 inspectional assessment pilot is also intended to generate information about recurring compliance themes, facility-specific risk signals, and discrepancies between registered and actual operations. This demonstrates the increasing importance of accurate regulatory information and effective quality-risk management.

Ultimately, FDA GMP Inspections in 2026 require organizations to move beyond reactive inspection preparation. A company that maintains accurate records, effective quality systems, strong data integrity, trained personnel, and evidence-based CAPA processes is better positioned to respond to both traditional inspections and newer targeted assessment models.

Conclusion

FDA’s inspection strategy is becoming more targeted, risk-based, and data-informed, but the fundamental objective remains unchanged: protecting patients by ensuring that regulated products are manufactured and controlled according to applicable requirements. Organizations should therefore make FDA Inspection Readiness an ongoing quality-system activity rather than a short-term preparation exercise.

By strengthening GMP Compliance, monitoring quality risks, maintaining inspection-ready documentation, training personnel, and addressing systemic issues before they escalate, companies can respond more effectively to evolving FDA oversight in 2026 and beyond.